RANKL Active Protein | TNFSF11 active protein

RANKL Protein, Human, Recombinant (rFc Tag)

Cat. Num. AAA8120915

• Gene Names: TNFSF11; ODF; OPGL; sOdf; CD254; OPTB2; RANKL; TRANCE; hRANKL2
• Purity: >85% as determined by SDS-PAGE
• Synonyms: RANKL; RANKL Protein; Human; Recombinant (rFc Tag); Human RANKL/OPGL/TNFSF11/CD254 Protein (Fc Tag); CD254 Protein; hRANKL2 Protein; ODF Protein; OPGL Protein; OPTB2 Protein; sOdf Protein; TRANCE Protein; tumor necrosis factor (ligand) superfamily; member 11; TNFSF11 active protein

• Host: HEK293 Cells
• Purity/Purification: >85% as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, pH7.4. Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Sequence: Gly63-Asp244

• Species: Human
• Endotoxin: <1.0EU per ug of the protein as determined by the LAL method
• Predicted N Terminal: Ser
• Tag: N-rabbit IgG-Fc
• Protein Construction: A DNA sequence encoding the human TNFSF11 (O14788-2)(Gly 63-Asp 244) was expressed with the Fc region of rabbit IgG at the N-terminus.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
• Activity: 1. Measured by its binding ability in a functional ELISA. Immobilized Human Osteoprotegerin His at 2ug/ml (100uL/well) can bind Human RANKL rFc. The EC50 of Human RANKL rFc is 3.0-15.0ng/mL.; 2. The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED50 for this effect is 1.5-7.5ng/mL.
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -20 degree C to -80 degree C. Store it under sterile conditions at -20 degree C to -80 degree C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.; In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid.; They are shipped out with blue ice.

SDS-Page

Testing Data

(Measured by its binding ability in a functional ELISA. Immobilized Human Osteoprotegerin His at 2 ug/ml (100 ul/well) can bind Human RANKL rFc, the EC50 of Human RANKL rFc is 3.0-15.0 ng/mL.)

Related Product Information for TNFSF11 active protein

Background: Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.

Product Categories/Family for TNFSF11 active protein

Cancer Drug Targets

References

Takayanagi H, et al. (2002) Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res. 4 Suppl 3: S227-32.
Nakashima T, et al. (2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7.
Schwarz EM, et al. (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther. 9 Suppl 1: S7.
Leibbrandt A, et al. (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.

NCBI and Uniprot Product Information

• NCBI GI #: 4507595
• NCBI GeneID: 8600
• NCBI Accession #: NP_003692.1
• NCBI GenBank Nucleotide #: NM_003701.3
• UniProt Accession #: O14788; O14723; Q96Q17; Q9P2Q3
• Molecular Weight: 35,478 Da
• NCBI Official Full Name: tumor necrosis factor ligand superfamily member 11 isoform 1
• NCBI Official Synonym Full Names: tumor necrosis factor (ligand) superfamily, member 11
• NCBI Official Symbol: TNFSF11
• NCBI Official Synonym Symbols: ODF; OPGL; sOdf; CD254; OPTB2; RANKL; TRANCE; hRANKL2
• NCBI Protein Information: tumor necrosis factor ligand superfamily member 11; osteoprotegerin ligand; osteoclast differentiation factor; TNF-related activation-induced cytokine; receptor activator of nuclear factor kappa B ligand; receptor activator of nuclear factor kappa-B ligan
• UniProt Protein Name: Tumor necrosis factor ligand superfamily member 11
• Protein Family: Tumor necrosis factor ligand superfamily
• UniProt Gene Name: TNFSF11
• UniProt Synonym Gene Names: OPGL; RANKL; TRANCE; ODF; OPGL; RANKL; TRANCE
• UniProt Entry Name: TNF11_HUMAN

NCBI Description

This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008]

Uniprot Description

TNFSF11: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Homotrimer. Up-regulated by T-cell receptor stimulation. Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. Belongs to the tumor necrosis factor family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral

Chromosomal Location of Human Ortholog: 13q14

Cellular Component: extracellular space; integral to plasma membrane; cytoplasm; extracellular region

Molecular Function: cytokine activity; tumor necrosis factor receptor superfamily binding; tumor necrosis factor receptor binding

Biological Process: ossification; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of osteoclast differentiation; cytokine and chemokine mediated signaling pathway; mammary gland epithelial cell proliferation; osteoclast differentiation; activation of JNK activity; positive regulation of homotypic cell-cell adhesion; positive regulation of corticotropin-releasing hormone secretion; activation of NF-kappaB transcription factor; calcium ion homeostasis; positive regulation of protein kinase B signaling cascade; positive regulation of MAP kinase activity; monocyte chemotaxis; organ morphogenesis; tumor necrosis factor-mediated signaling pathway; positive regulation of bone resorption; positive regulation of transcription factor activity; immune response; positive regulation of transcription from RNA polymerase II promoter; positive regulation of T cell activation; protein homooligomerization; bone resorption

Disease: Osteopetrosis, Autosomal Recessive 2